You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Norwegian company Photocure announces that the first patient has been enrolled in the Hexvix/Cysview Market Expansion Phase 3 study on bladder cancer. The study will investigate the use of Hexvix/Cysview in the outpatient / surveillance setting and is designed to fulfill the FDA post marketiAlready a subscriber Login You have…
Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to Already a subscriber Login You have read all…
Nordic Nanovector announces that the first patient has been enrolled into one of the two new arms of its expanded Lymrit 37-01 clinical study with Betalutin. Betalutin is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin’sAlready a subscriber Login You have…
Monday December 9th, Moberg Pharma announced results from the first study in the Phase 3 program for MOB-015, where the primary endpoint and the two key secondary endpoints were met. However, the results were somewhat contradictory and the company has clarified the various study parameters as well aAlready a subscriber…
